Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 3:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Cancer Clear all
Recruiting Phase 1Phase 2 Interventional

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

NCT05902988
View directory record Official record
Conditions
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions
VLS-1488
Drug
Lead sponsor
Volastra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 20, 2026, 3:49 PM EDT
Completed No phase listed Observational

Olympus - 19-gauge Needle

NCT03270670
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

NCT00093756
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, bortezomib, paclitaxel, carboplatin
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
143
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Not applicable Interventional Results available

Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis

NCT04040244
View directory record Official record
Conditions
Pneumonitis, Nonsmall Cell Lung Cancer Stage III
Interventions
Exhaled Breath Collection, Blood sample
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

NCT00565721
View directory record Official record
Conditions
High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma
Interventions
Fluciclatide Injection - (AH111585 (F18))
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Not applicable Interventional Results available

Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients

NCT04397614
View directory record Official record
Conditions
Sars-CoV2, Covid-19
Interventions
mHealth Assessments
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 3 Interventional

Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

NCT00004199
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, gemcitabine hydrochloride, prinomastat
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Not applicable Interventional Results available

Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies

NCT02702921
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Surgeon's 'standard of care' stapler, Ethicon Powered Vascular Stapler
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1 Interventional

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

NCT04982926
View directory record Official record
Conditions
Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Interventions
TAS2940
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1 Interventional

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

NCT04244552
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Acral Lentiginous Melanoma, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, Esophageal Squamous Cell Carcinoma, Urothelial Carcinoma, DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Melanoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer
Interventions
ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD)
Biological · Drug
Lead sponsor
Atreca, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 20, 2026, 3:49 PM EDT
Recruiting Phase 1Phase 2 Interventional

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Cancer

NCT07224152
View directory record Official record
Conditions
Locally-Advanced Non-Small Cell Lung Cancer
Interventions
NBTXR3
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 20, 2026, 3:49 PM EDT
Not listed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

NCT00006458
View directory record Official record
Conditions
Lung Cancer
Interventions
indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Belleville, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene

NCT05469178
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Bemcentinib, Pembrolizumab, Pemetrexed, Carboplatin
Drug
Lead sponsor
BerGenBio ASA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Miami Beach, Florida • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemotherapy and Proton Radiation for the Treatment of Locally Advanced Lung Cancer

NCT00614484
View directory record Official record
Conditions
Locally Advanced Non-Small Cell Lung Cancer
Interventions
Proton Radiation Therapy, Taxol, Carboplatin
Radiation · Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1 Interventional

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

NCT00288444
View directory record Official record
Conditions
Lung Cancer, Soft Tissue Sarcoma, Colorectal Carcinoma, Breast Cancer, Prostate Cancer
Interventions
Lonafarnib, Docetaxel
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 20, 2026, 3:49 PM EDT
Terminated Phase 1 Interventional

A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response

NCT01258634
View directory record Official record
Conditions
Osteosarcoma, Lung Metastases
Interventions
Dexrazoxane, Doxorubicin, Cisplatin, G-CSF, PEG-filgrastim, Etoposide, Ifosfamide, Mesna, Leucovorin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Years to 35 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Sep 20, 2026, 3:49 PM EDT
Recruiting Phase 4 Interventional

Dabrafenib and/or Trametinib Rollover Study

NCT03340506
View directory record Official record
Conditions
Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers, High Grade Glioma
Interventions
dabrafenib, trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
4
States / cities
Scottsdale, Arizona • Bethesda, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 20, 2026, 3:49 PM EDT
Active, not recruiting No phase listed Observational

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

NCT06538038
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Interventions
Osimertinib, Osimertinib + Chemotherapy
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
146
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Jonesboro, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 20, 2026, 3:49 PM EDT
Not listed Early Phase 1 Interventional

Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

NCT02619448
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Paclitaxel, 70 Gy in 20 fractions over 4 weeks
Drug · Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Treatment for Advanced Non-Small Cell Lung Cancer

NCT00073398
View directory record Official record
Conditions
Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma, Lung Neoplasms
Interventions
Drug: Hyperacute Lung Cancer Cell Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 20, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

NCT02572687
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
Ramucirumab, MEDI4736
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 20, 2026, 3:49 PM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

NCT00909558
View directory record Official record
Conditions
Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
Interventions
Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Biological
Lead sponsor
Envita Medical Center, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Sep 20, 2026, 3:49 PM EDT